Trend-Following Backtester · Guide · backtest 한국어

equity · DE

Redcare Pharmacy N.V. backtest

10 trend-following strategies were compared on the full daily history of Redcare Pharmacy N.V.. 8 beat buy-and-hold CAGR; EMA 크로스오버 ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is 볼린저 밴드 돌파 (CAGR 12.9%, MDD -22.8%).

Data 2017-08-09 ~ 2026-07-31daily bars 2,280 (9.0 years)Costs 0.5%Venue XETRMonthly snapshot 2026-07-31

Results by strategy

8 of 10 beat buy and hold (CAGR 5.1%, drawdown -87.5%).

Sharpe leader (same as main): EMA 크로스오버 — CAGR 21.8%, MDD -44.5%, Sharpe 0.74, 42% exposure.

Return/drawdown alternative: 볼린저 밴드 돌파 — CAGR is 16.7%p higher than buy and hold, while drawdown improves by 42.9%p (CAGR 12.9%, MDD -22.8%, exposure 11%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
EMA 크로스오버
fast=19, slow=122
21.8%-44.5%0.740.495.9x1342%
볼린저 밴드 돌파
n=57, k=3.5
12.9%-22.8%0.700.573.0x611%
SMA 크로스오버
fast=8, slow=148
18.5%-51.7%0.660.364.6x2143%
Donchian 채널 돌파
entryN=113, exitN=66
16.8%-45.6%0.640.374.0x937%
Keltner 채널 돌파
emaPeriod=44, atrPeriod=20, mult=2.3
12.5%-35.3%0.560.362.9x3329%
ADX / DI 방향성
period=16, threshold=29
10.1%-32.8%0.550.312.4x3617%
ROC 모멘텀
n=107, threshold=0.05
12.4%-57.7%0.510.212.9x5140%
Supertrend
period=17, mult=3.5
6.0%-74.4%0.350.081.7x4749%
Parabolic SAR
step=0.005, maxStep=0.3
4.1%-69.3%0.300.061.4x7950%
MACD
fast=12, slow=34, signal=19
-2.2%-69.0%0.16-0.030.8x12254%
Buy and hold5.1%-87.5%0.370.061.6x1100%
1x 2018 2020 2022 2024 2026 EMA 크로스오버Buy and hold
EMA 크로스오버: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -22% -44% -66% -87% 2018 2020 2022 2024 2026 Buy and holdEMA 크로스오버
EMA 크로스오버 maximum drawdown -44.5% (2021-02-15 → 2021-12-10), recovered after 897 days.

Rules of the top strategy

Uses two exponential averages (more weight on recent prices) and trades their crossover.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next